Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-20 07:27 1883

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-18 05:54 2474

Telix Full Year Results 2025 Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2026-02-04 05:38 5103

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ...

2026-01-29 07:43 4519

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Li...

2026-01-20 15:16 8024

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-20 06:15 4100

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-17 03:21 3855

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2026-01-08 19:00 8585

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-12-22 05:40 3964

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Lim...

2025-12-11 03:30 2009

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2025-12-08 06:08 1383

Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-11-21 14:22 3351

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-11-20 03:00 1536

Latest News

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

Telix Full Year Results 2025 Investor Webcast Notification

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

Telix Announces Record-Breaking Presence at EANM 2025

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth